Diflucan Capsules, Diflucan Capsules, Powder For Oral Suspension 50 mg, 150 mg and 200 mg & 50 mg/5 mL and 200 mg/5 mL CAPSULES, INFUSION,
PDF Leaflet Revision Date: 31 Jan 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of fungal infections including cryptococcal meningitis and candidiasis.
Dosage (summary)
400 mg on day 1, then 200 mg daily for cryptococcal meningitis; 150 mg as a single dose for vaginal candidiasis.
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy; found in breast milk.
Key Drug Interactions
- Terfenadine
- Cisapride
- Erythromycin
Contraindications
- Hypersensitivity to fluconazole
- Co-administration with terfenadine at high doses
Common side effects
- Headache
- Nausea
- Rash
Counselling Points
- Monitor for liver function
- Avoid in pregnancy
- Use effective contraception during treatment
Serious warnings
- Hepatotoxicity
- QT prolongation
Important Disclaimer
The Diflucan Capsules, Diflucan Capsules, Powder For Oral Suspension 50 mg, 150 mg and 200 mg & 50 mg/5 mL and 200 mg/5 mL CAPSULES, INFUSION, professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
